The most highly expressed cytokine after DSS treatment in Gli1+/lacZ animals was IL-23p19, a molecule that drives differentiation of TH17 lymphocytes, key mediators of inflammation in several systems, including IBD [39,40]. Here, GLI1 is linked to inflammatory bowel disease.